References
- Bernstein BE, Tong JK, Schreiber SL. Genomewide studies of histone deacetylase function in yeast. Proc Natl Acad Sci USA 2000;97:13708–13.
- de Ruijter AJ, van Gennip AH, Caron HN, et al. Histone deacetylases (HDACs): Characterization of the classical HDAC family. Biochem J 2003;370:737–49.
- Foglietti C, Filocamo G, Cundari E, et al. Dissecting the biological functions of drosophila histone deacetylases by RNA interference and transcriptional profiling. J Biol Chem 2006;281:17968–76.
- Zhang L, Han Y, Jiang Q, et al. Trend of histone deacetylase inhibitors in cancer therapy: Isoform selectivity or multitargeted strategy. Med Res Rev 2015;35:63–84.
- Yun F, Cheng C, Ullah S, et al. Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity. Eur J Med Chem 2019;176:195–207.
- Marks P, Rifkind RA, Richon VM, et al. Histone deacetylases and cancer: Causes and therapies. Nat Rev Cancer 2001;1:194–202.
- Zhang L, Chen Y, Jiang Q, et al. Therapeutic potential of selective histone deacetylase 3 inhibition. Eur J Med Chem 2019;162:534–42.
- Zhang L, Fang H, Xu W. Strategies in developing promising histone deacetylase inhibitors. Med Res Rev 2010;30:585–602.
- Marks PA. Discovery and development of SAHA as an anticancer agent. Oncogene 2007;26:1351–6.
- Grant C, Rahman F, Piekarz R, et al. Romidepsin: A new therapy for cutaneous t-cell lymphoma and a potential therapy for solid tumors. Expert Rev Anticancer Ther 2010;10:997–1008.
- Rashidi A, Cashen AF. Belinostat for the treatment of relapsed or refractory peripheral t-cell lymphoma. Future Oncol 2015;11:1659–64.
- Greig SL. Panobinostat: A review in relapsed or refractory multiple myeloma. Target Oncol 2016;11:107–14.
- Galkin AV, Melnick JS, Kim S, et al. Identification of nvp-tae684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proc Natl Acad Sci USA 2007;104:270–5.
- Huang WS, Liu S, Zou D, et al. Discovery of brigatinib (ap26113), a phosphine oxide-containing, potent, orally active inhibitor of anaplastic lymphoma kinase. J Med Chem 2016;59:4948–64.
- Gao Y, Zhang H, Lirussi F, et al. Y dual inhibitors of histone deacetylases and other cancer-related targets: a pharmacological perspective. Biochem Pharmacol 2020;182:114224.
- He X, Hui Z, Xu L, et al. Medicinal chemistry updates of novel HDACs inhibitors (2020 to present). Eur J Med Chem 2022;227:113946.
- Fan W, Zhang L, Wang X, et al. Discovery of potent histone deacetylase inhibitors with modified phenanthridine caps. J Enzyme Inhib Med Chem 2021;36:707–18.